Pediatric Surgery International

, Volume 23, Issue 4, pp 331–335 | Cite as

Phimosis and topical steroids: new clinical findings

  • Nicola ZampieriEmail author
  • Michele Corroppolo
  • Veronica Zuin
  • Sanzio Bianchi
  • Francesco Saverio Camoglio
Original Article


Phimosis has been defined as unretractable foreskin without adherences and/or a circular band of tight prepuce preventing full retraction. The aim of this study is to evaluate the efficacy (response rate) of topical steroids for the treatment of tight phimosis at different age stages. After using the same medication with different dosage schemes, a retrospective analysis was carried out to assess the efficacy of topical steroids in the treatment of tight phimosis. Patients were divided into three groups: group A (betamethasone scheme A), group B (betamethasone scheme B) and group C (control group). Remission of phimosis, with a complete exposure and without a narrowing behind the glans, was considered a complete response to treatment. The outcomes were then related to dosage scheme and patient’s age. The dosage for group A was more effective than the dosage for groups B and C (control group). Phimosis resolved in 90% (group A), 72% (group B) and 56% (group C) of cases. A successful treatment was closely related to the age of patients at the beginning of steroid application. The results showed that treatment with topical steroids, which in general gives good results, proved to be much more successful in patients aged between 4 and 8 years, suggesting the efficacy of an early beginning of the treatment.


Phimosis Topical steroids Non-operative treatment 


  1. 1.
    Jorgensen ET, Svenson A (1993) The treatment of phimosis in boys with a potent topical steroid (clobetsol propinate 0.05%) cream. Acta Derm Venerol 3:673–676Google Scholar
  2. 2.
    Monsour MA, Rabinovitch HH, Dean GE (1999) Medical management of phimosis in children: our experience with topical steroids. J Urol 162:1162–1164PubMedCrossRefGoogle Scholar
  3. 3.
    Atilla MK, Dundaroz R, Odabas O, Ozturk H et al (1997) A non surgical approach to the treatment of phimosis: local nonsteroidal anti-inflammatory ointment application. J Urol 158:196–197PubMedCrossRefGoogle Scholar
  4. 4.
    Chu CC, Chen KC, Diau GY (1999) Topical steroid treatment of phimosis in boys. J Urol 162:861–863PubMedCrossRefGoogle Scholar
  5. 5.
    Iken A, Ben Mouelli S, Fontaine E, Quenneville V et al (2002) Treatment of phimosis with locally applied 0.05% clobetasol propionate. Prospective study with 108 children. Prog Urol 12:1268–1271PubMedGoogle Scholar
  6. 6.
    Van Basten JP, De Vijlder AM, Mensink HJ (2003) The use of corticosteroid cream to treat phimosis. Ned Tijdschr Geneeskd 147:1544–1547PubMedGoogle Scholar
  7. 7.
    Elmore JM, Baker LA, Snodgrass WT (2002) Topical steroid therapy as an alternative to circumcision for phimosis in boys younger than 3 years. J Urol 168:1746–1747PubMedCrossRefGoogle Scholar
  8. 8.
    Ashfield JE, Nickel KR, Siemens DR, MacNeily AE, Nickel JC (2003) Treatment of phimosis with topical steroids in 194 children. J Urol 169:1106–1108PubMedCrossRefGoogle Scholar
  9. 9.
    Orsola A, Caffaratti J, Garat JM (2000) Conservative treatment of phimosis in children using a topical steroid. Urology 56:307–310PubMedCrossRefGoogle Scholar
  10. 10.
    Webster TM, Leonard MP (2002) Topical steroid therapy for phimosis. Can J Urol 9:1492–1495PubMedGoogle Scholar
  11. 11.
    Kikiros CS, Beasley SW, Woodward AA (1993) The response of phimosis to local steroid application. Pediatr Surg Int 8:329–332CrossRefGoogle Scholar
  12. 12.
    Gainder D (1949) The fate of the foreskin. BMJ 2:1433–1437Google Scholar
  13. 13.
    Rickwood AMK, Hemalatha V, Batcup G, Spitz L (1980) Phimosis in boys. Br J Urol 52:147–150PubMedCrossRefGoogle Scholar
  14. 14.
    Kayaba H, Tamura H, Kitajima S, Fujiwara Y, Kato T, Kato T (1996) Analysis of shape and retractability of the prepuce in 603 japanese boys. J Urol 156:1813–1815PubMedCrossRefGoogle Scholar
  15. 15.
    Zampieri N, Corroppolo M, Camoglio FS, Giacomello L, Ottolenghi A (2005) Phimosis: stretching methods with or without application of topical steroids? J Pediatr 147(5): 705–706PubMedCrossRefGoogle Scholar
  16. 16.
    Miller JA, Munro DD (1980) Topical corticosteroids: clinical pharmacology and therapeutic use. Drugs 19:119–134PubMedGoogle Scholar
  17. 17.
    Brazzini B, Pimpinelli N (2002) New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 3:47–58PubMedCrossRefGoogle Scholar
  18. 18.
    Rao LS, Long WS, Kaneko T, Blumenberg M (2003) Regulation of trascription factor activity by extracellular signals in epidermal keratinocytes. Acta Dermatoven 12:3–14Google Scholar
  19. 19.
    Radoja N, Nomine M, Jho SH, Blumenberg M, Tomic-canic M (2000) Novel mechanism of steroid action in skin through glucocorticoid receptor monomers. Mol Cell Biol 20:4328–4339PubMedCrossRefGoogle Scholar
  20. 20.
    Austin RJH, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ (2002) Mometasone fuorate is a less specific glucocorticoid than fluticonasone propionate. Eur Respir J 20:1386–1392PubMedCrossRefGoogle Scholar
  21. 21.
    Croxtall JD, Paul-Clark M, Van Hall PTW (2003) Differential modulation of glucorticoid action by FK506 in A549 cells. Biochem J 376:285–290PubMedCrossRefGoogle Scholar
  22. 22.
    Panarelli M, Holloway CD, Fraser R, Connell JMC, Ingram MC, Anderson NH, Kenyon CJ (1998) Glucorticoid receptor polymorphism, skin vasoconstriction and other metabolic intermediate phenotypes in normal human subjects. J Clin Endocrinol Metab 83:1846–1852PubMedCrossRefGoogle Scholar
  23. 23.
    Bonacci JV, Harris T, Wilson JW, Stewart AG (2003) Collagen-induced resistance to glucocorticoid anti-mitogenic actions: a potential explanation of smooth muscle hyperplasia in the asthmatic remodeled airway. Br J Pharmacol 138:1203–1206PubMedCrossRefGoogle Scholar
  24. 24.
    Oikarien A, Salo T, Ala-Kokko L, Tryggvason K (1987) Dexamethasone modulates the metabolism of type IV collagen and fidronectin in human basement-membrane-forming fibrosarcoma (HT-1080) cells. J Biochem 245:235–241Google Scholar
  25. 25.
    Barnes PJ (1998) Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 94:557–572PubMedGoogle Scholar
  26. 26.
    Gysler A, Kleuser B, Sippl W, Lange K, Korting HC, Holtje HD, Schafer-Korting M (1999) Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm Res 16:1386–1391PubMedCrossRefGoogle Scholar
  27. 27.
    Oikarinen A, Oikarinen H, Tan EM, Uitto J (1987) Modulation of collagen metabolism in cultured human skin fibroblasts by dexamethasone: correlation with glucocorticoid receptor density. Acta Derm Venereol 67:106–115PubMedGoogle Scholar
  28. 28.
    EFL (2005) Clinical potencies of glucocorticoids: what do we really measure? Curr Respir Med Rev 1:103–108Google Scholar
  29. 29.
    Bray PL, Du B, Mejia VM, Hao SC, Deutsch E, Fu C, Wilson RC, Hanauske-Abel H, McCaffrey TA (1999) Glucocorticoid resistance caused by reduced expression of the glucorticoid receptor in cells from human vascular lesions. Arterioscler Thromb Vasc Biol 19:1180–1189PubMedGoogle Scholar
  30. 30.
    Jefferson G, Lond MS, Victoria FRCS BC (1916) The peripenic muscle: some observations on the anatomy of phimosis. Surg Gynecol Obstet 23(2):177–181Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Nicola Zampieri
    • 1
    • 2
    Email author
  • Michele Corroppolo
    • 1
  • Veronica Zuin
    • 1
  • Sanzio Bianchi
    • 1
  • Francesco Saverio Camoglio
    • 1
  1. 1.Department of Surgical Sciences, Paediatric Surgical UnitUniversity of VeronaVeronaItaly
  2. 2.Paediatric Surgical UnitPoliclinico “G. B. Rossi”VeronaItaly

Personalised recommendations